CN106377571A - Method for preparing pharmaceutical composition of milkvetch root injection preparation - Google Patents
Method for preparing pharmaceutical composition of milkvetch root injection preparation Download PDFInfo
- Publication number
- CN106377571A CN106377571A CN201610968063.5A CN201610968063A CN106377571A CN 106377571 A CN106377571 A CN 106377571A CN 201610968063 A CN201610968063 A CN 201610968063A CN 106377571 A CN106377571 A CN 106377571A
- Authority
- CN
- China
- Prior art keywords
- injection
- fruit acid
- radix astragali
- preparation
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a method for preparing a pharmaceutical composition of an milkvetch root injection preparation. The pharmaceutical composition is a pharmaceutical composition for injection prepared by dissolving salts of milkvetch root into water for injection, adding tartaric acid and/or sodium tartaric acid serving as a pH regulator to regulate the pH value of the liquid medicine, wherein the amount of tartaric acid and/or sodium tartaric acid is 0.1-200.0mg/100ml. According to the method, the pH value of the injection can be stable, milkvetch root degradation materials are greatly reduced compared with those in the prior art, the clarity of the milkvetch root injection is improved under the condition that other cosolvents capable of increasing clinical application risk are not used, particularly the problems of small white dots, white blocks and turbid solution occurring in the existing technical products under the condition that the storage time is long are solved, visible foreign matters in the product can be inspected to comply with provisions of drug quality standards, and the composition facilitates clinical administration and popularization.
Description
Technical field
A kind of the invention belongs to pharmaceutical technology field, in particular it relates to preparation side of astragalus injection preparation medicine compositionss
Method.
Background technology
The Radix Astragali is the alkaloid extracting from chuanxiong, and chemical constitution is tetramethylpyazine, is a kind of novel agents of calcium ion
Antagonist, has blood circulation promoting and blood stasis dispelling, anti-platelet aggregation, excited medullary respiratory center and vasomotor center, expansion of blood vessels and props up
Tracheal smooth muscle, improve multiple effect such as microcirculation, be clinically used for for obliterated cerebral vascular disease such as incomplete brain blood supply, brain blood
Bolt formation, cerebral embolism and other ischemic angiopathys such as coronary heart disease, vasculitiss etc..The injection of the Radix Astragali has been Chinese medicine
Modern hardly possible disease makes very big contribution.
Due to Radix Astragali dissolubility extreme difference in aqueous, therefore it is made into Radix Astragali hydrochlorate or Radix Astragali phosphate to increase
Its water solublity.Presently commercially available Radix Astragali injection mainly has the phosphatic injection with small volume of Radix Astragali hydrochlorate, the Radix Astragali, Yi Ji
Glucose or sodium chloride is added to inject as the Large Copacity that osmotic pressure regulator is made in Radix Astragali hydrochlorate, Radix Astragali phosphate solution
Liquid.But when preparing above-mentioned injection it is necessary to the pH value of medicinal liquid is adjusted to the certain limit of suitable human injection's administration, at present
The pH value regulator that document report uses is sodium hydroxide solution or uses hydrochloric acid solution, phosphoric acid solution, but adopts above-mentioned pH
The Radix Astragali injection of value regulator preparation easily separates out tiny white point, white block, solution under the conditions of long-term storage and winter low temperature
The precipitate such as muddiness, cause the visible foreign matters check item of product unqualified.Prior art is to add polyoxyethylene sorbitan monoleate in the solution
As cosolvent, to solve product, the sedimentary problems such as small particles, white block, solution muddiness occur.But polyoxyethylene sorbitan monoleate due to
There is the effect of haemolysis and blood pressure lowering, and easily become sour in storage and autoclaving process, lead to the note containing polyoxyethylene sorbitan monoleate
Penetrate liquid clinical practice risk higher, make troubles to clinical application and popularization.
Content of the invention
The technical problem to be solved is to provide a kind of preparation method of astragalus injection preparation medicine compositionss.
This medicinal composition for injections adopts fruit acid, fruit acid sodium as pH adjusting agent, and finds to adopt by creative work
During with fruit acid, fruit acid sodium as pH adjusting agent, medicinal liquid pH value is more stable, and Radix Astragali degradation material substantially reduces compared with prior art,
In the case of avoiding increasing the cosolvent of clinical practice risk using other, Radix Astragali injection is satisfactorily addressed and has grown
Tiny white point, white block, the problem of solution muddiness is easily separated out under the conditions of phase storage and winter low temperature.
The present invention solves the above problems and be employed technical scheme comprise that：
A kind of preparation method of astragalus injection preparation medicine compositionss, comprises the steps：
(1) salt weighing the Radix Astragali is with Radix Astragali amount of calculation 0.1g～100g, fruit acid and/or fruit acid sodium 2mg～4.0g；
(2) fruit acid, fruit acid sodium are configured to the solution of 10g/100ml～20g/100ml respectively, standby；
(3) salt of the Radix Astragali, sodium chloride add in 30 DEG C～40 DEG C of water for injection 500ml, stir to after be completely dissolved, plus
The activated carbon entering, described activated carbon dosage is 0.02g/100ml, stirs 15 minutes, filters decarburization；
(4) step (3) gained filtrate step (2) configures fruit acid and/or fruit acid sodium solution adjust pH value be 3.0～
7.0, the water for injection adding less than 40 DEG C (30 DEG C～40 DEG C) is to 1000ml；
(5) by step (4) gained medical filtration to clarification, fill, sterilizing, obtain final product.
In described step (1) fruit acid consumption be 1mg～2.0g, fruit acid sodium consumption be 1mg～2.0g.
Osmotic pressure regulator 9.0g is also included in described step (1).
Described osmotic pressure regulator is sodium chloride.
In such scheme, add that fruit acid and/or fruit acid sodium refers to add can be fruit acid, any one in fruit acid sodium,
Or fruit acid, fruit acid sodium are with arbitrary proportion proportioning；In step (2), one of the fruit acid of addition, fruit acid sodium, then make
A kind of solution, such as includes fruit acid, two kinds of fruit acid sodium, is then configured to solution for standby respectively；The salt of the Radix Astragali, the use of osmotic pressure regulator
Amount can adopt the consumption of prior art, according to the consumption adjustment of prior art.
In sum, the invention has the beneficial effects as follows：The present invention pass through experimental studies have found that, in Radix Astragali drug injection preparation
In, during using fruit acid, fruit acid sodium as pH adjusting agent, medicinal liquid pH value is more stable, and Radix Astragali degradation material is compared with prior art significantly
Reduce, in the case of avoiding increasing the cosolvent of clinical practice risk using other, astragalus injection has been satisfactorily addressed
Liquid adopts prior art products easily to separate out the muddy problem of tiny white point, white block, solution in storage process it is ensured that Huang
Astragalus injection liquid can be stable in storage process the visible foreign matters detection of holding injection meet the regulation of drug standard,
It is easy to clinical application and popularization.
The present invention passes through creative work, the reason muddy to the tiny white point separating out in Radix Astragali injection, white block, solution
It is analyzed and studies, determine that deposit is mainly raw material free alkali crystallize and a small amount of catabolite, above-mentioned reason can
Can be relevant with species sour, alkali used by the pH value of solution and pH adjusting agent.Fruit acid sodium is therefore used as pH adjusting agent, and makes
With fruit acid as pH value counter regulation agent, in the case of avoiding increasing the cosolvent of clinical practice risk using other, to solve
This product muddy problem of the tiny white point of easy precipitation, white block, solution under the conditions of long-term storage and winter low temperature.
Specific embodiment
With reference to embodiment, the present invention is described in further detail, but embodiments of the present invention not limited to this.
Embodiment 1
A kind of preparation method of astragalus injection preparation medicine compositionss, comprises the steps：(1) weigh crude drug with the Radix Astragali
Amount of calculation 0.1g～100g, sodium chloride 9.0g, fruit acid 1mg～2.0g, fruit acid sodium 1mg～2.0g；(2) fruit acid, fruit acid sodium difference
It is configured to 10%～20% solution, standby.(3) add in less than 40 DEG C of water for injection 500ml, stir to being completely dissolved
Afterwards, add the activated carbon of 0.02% (g/ml), stir 15 minutes, filter decarburization.(4) filtrate fruit acid or fruit acid sodium solution are adjusted
PH value is 3.0～7.0, adds less than 40 DEG C of water for injection to 1000ml；(5) medical filtration, to clarification, fill, sterilizes, that is,
?.
Specifically the composition of each component and its content are as follows for the present embodiment：
Fruit acid, fruit acid sodium are configured to 10%～20% solution respectively, standby.The hydrochloric acid Radix Astragali, sodium chloride add 40 DEG C with
Under water for injection 500ml in, stir to after be completely dissolved, add 0.02% activated carbon (i.e. activated carbon dosage be 0.02g/
100ml), stir 15 minutes, filter decarburization.Filtrate fruit acid or fruit acid sodium solution adjust pH value for 3.8～4.2, add 40 DEG C
Following water for injection is to 1000ml.Medical filtration, to clarification, fill, sterilizing, obtains final product.
Embodiment 2
Or, a kind of preparation method of astragalus injection preparation medicine compositionss：
(1) weigh crude drug with Radix Astragali amount of calculation 0.1g～100g, fruit acid 1mg～2.0g, fruit acid sodium 1mg～2.0g；(2)
Fruit acid, fruit acid sodium are configured to 10%～20% solution respectively, standby.(3) add in less than 40 DEG C of water for injection 500ml,
Stir to after be completely dissolved, add the activated carbon of 0.02% (g/ml), stir 15 minutes, filter decarburization.(4) filtrate fruit acid or
It is 3.0～7.0 that fruit acid sodium solution adjusts pH value, adds less than 40 DEG C of water for injection to 1000ml；(5) medical filtration is extremely clear
Clearly, fill, sterilizing, obtain final product.
Specifically the composition of each component and its content are as follows for the present embodiment：
Hydrochloric acid Radix Astragali 20g
Fruit acid 1.0g
Fruit acid sodium 2.0g
Fruit acid, fruit acid sodium are configured to 10%～20% solution respectively, standby.The hydrochloric acid Radix Astragali adds less than 40 DEG C of injection
With in water 500ml, stirring to after be completely dissolved, add 0.02% activated carbon (i.e. activated carbon dosage is 0.02g/100ml), stir
Mix 15 minutes, filter decarburization.Filtrate fruit acid or fruit acid sodium solution adjust pH value for 3.8～4.2, add less than 40 DEG C of injection
With water to 1000ml.Medical filtration, to clarification, fill, sterilizing, obtains final product.
Embodiment 3
Radix Astragali sodium chloride injection stability comparative test
Visible foreign matters detection using Radix Astragali sodium chloride injection obtained by the present invention meets the regulation of drug standard,
And stability of solution is very well, in the case of avoiding increasing the cosolvent of clinical practice risk using other, solve Radix Astragali chlorine
Change sodium injection and the problems such as small particles, white block, solution muddiness easily occurs in storage process.Using the Radix Astragali obtained by the present invention
Sodium chloride injection is according to the correlation of two annex of China's coastal port Ⅺ Ⅹ C pharmaceutical preparation stability test guideline
Require, investigated respectively 25 DEG C place place within 24 months, 40 DEG C place within 6 months, 60 DEG C 10 days, 0～5 DEG C of low temperature places 20 days
Medicine stability, product quality is stable at the conditions of the experiments described above for result, and every Testing index all meets this product quality standard
Regulation.
The pharmacological results show：Using the no hemolytic, no of the stable Radix Astragali sodium chloride injection obtained by the present invention
Anaphylaxis, nonirritant, meet the requirement of drug administration by injection.
1 25 DEG C of study on the stability results of table
Table 2 60 DEG C of study on the stability results of hydrochloric acid Radix Astragali sodium chloride injection
3 40 DEG C of study on the stability results of table
4 0～5 DEG C of low temperature visible foreign matters of table investigate result
According to the above results, the Radix Astragali drug injection preparation of the present invention can improve the clarity of Radix Astragali injection,
Particularly in the case that astragalus injection period of storage is longer, the visible foreign matters detection of holding injection that can be stable meets medicine
The regulation of quality standard, solves Radix Astragali medicine and little Bai using existing technical products in the case that period of storage is longer
The muddy problem of point, white block, solution, it is ensured that the visible foreign matters inspection of product meets the regulation of drug standard, is easy to
Clinical application and popularization.
As described above, just can preferably realize the present invention.
Claims (4)
1. a kind of preparation method of astragalus injection preparation medicine compositionss is it is characterised in that comprise the steps：
（1）The salt weighing the Radix Astragali is with Radix Astragali amount of calculation 0.1g～100g, fruit acid and/or fruit acid sodium 2mg～4.0g；
（2）Fruit acid, fruit acid sodium are configured to the solution of 10g/100ml～20g/100ml respectively, standby；
（3）The salt of the Radix Astragali, sodium chloride add in 30 DEG C～40 DEG C of water for injection 500ml, stir to after be completely dissolved, addition
Activated carbon, described activated carbon dosage is 0.02g/100ml, stirs 15 minutes, filters decarburization；
（4）Step（3）Gained filtrate step（2）The fruit acid of configuration and/or fruit acid sodium solution adjust pH value for 3.0～7.0, plus
Enter less than 40 DEG C of water for injection to 1000ml；
（5）By step（4）Gained medical filtration, to clarification, fill, sterilizing, obtains final product.
2. a kind of preparation method of astragalus injection preparation medicine compositionss according to claim 1 is it is characterised in that institute
State step（1）Middle fruit acid consumption is 1mg～2.0g, fruit acid sodium consumption is 1mg～2.0g.
3. a kind of astragalus injection preparation medicine compositionss according to claim 1 and 2 preparation method it is characterised in that
Described step（1）In also include osmotic pressure regulator 9.0g.
4. a kind of preparation method of astragalus injection preparation medicine compositionss according to claim 3 is it is characterised in that described
Osmotic pressure regulator is sodium chloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610968063.5A CN106377571A (en) | 2016-11-06 | 2016-11-06 | Method for preparing pharmaceutical composition of milkvetch root injection preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610968063.5A CN106377571A (en) | 2016-11-06 | 2016-11-06 | Method for preparing pharmaceutical composition of milkvetch root injection preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106377571A true CN106377571A (en) | 2017-02-08 |
Family
ID=57957229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610968063.5A Withdrawn CN106377571A (en) | 2016-11-06 | 2016-11-06 | Method for preparing pharmaceutical composition of milkvetch root injection preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106377571A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102008727A (en) * | 2010-12-07 | 2011-04-13 | 四川升和药业股份有限公司 | Injection-purpose medicine composition for improving stability of ligustrazine medicine injection formulation and preparation method of injection-purpose medicine composition |
| CN105106110A (en) * | 2015-09-23 | 2015-12-02 | 成都艾比科生物科技有限公司 | Injectable medicine composition capable of improving stability of puerarin medicine injection preparation and preparation method of injectable medicine composition |
-
2016
- 2016-11-06 CN CN201610968063.5A patent/CN106377571A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102008727A (en) * | 2010-12-07 | 2011-04-13 | 四川升和药业股份有限公司 | Injection-purpose medicine composition for improving stability of ligustrazine medicine injection formulation and preparation method of injection-purpose medicine composition |
| CN105106110A (en) * | 2015-09-23 | 2015-12-02 | 成都艾比科生物科技有限公司 | Injectable medicine composition capable of improving stability of puerarin medicine injection preparation and preparation method of injectable medicine composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008727B (en) | Injection-purpose medicine composition for improving stability of ligustrazine medicine injection formulation | |
| CN105106110A (en) | Injectable medicine composition capable of improving stability of puerarin medicine injection preparation and preparation method of injectable medicine composition | |
| CN105125485A (en) | Preparation method of injecting drug improving stability of puerarin drug injection preparation | |
| CN106361969A (en) | Preparation method of drug composition for improving stability of Shengmai drug injection preparation | |
| CN105963247A (en) | Preparation method of injection medicine for improving stability of quercetin medicine injection preparation | |
| CN106361693A (en) | Preparation method of leech injection preparation pharmaceutical composition | |
| CN106344636A (en) | Preparation method of Chinese thorowax root injection preparation pharmaceutical composition | |
| CN106344502A (en) | Pharmaceutical composition for injection capable of improving stability of leech drug injection preparation | |
| CN106377571A (en) | Method for preparing pharmaceutical composition of milkvetch root injection preparation | |
| CN106474056A (en) | A kind of medicinal composition for injections improving phylloxanthin drug injection preparation stability | |
| CN106389315A (en) | Injection pharmaceutical composition for improving stability of sharpleaf galangal fruit drug injection preparation | |
| CN106361803A (en) | Pharmaceutical composition for injection for improving stability of Astragalus membranaceus medicine injection preparation | |
| CN106361692A (en) | Injection pharmaceutical composition capable of enhancing radix bupleuri pharmaceutical injection preparation stability | |
| CN106511424A (en) | Preparation method of herba artemisiae annuae injection preparation medicinal composition | |
| CN106389321A (en) | Pharmaceutical composition capable of improving stability of Shenmai drug injection | |
| CN107823130A (en) | A kind of preparation method of tetrandrine injection agent medicine composition | |
| CN106361855A (en) | Method for preparing pharmaceutical composition of Yinzhihuang injection | |
| CN106389316A (en) | Injection pharmaceutical composition capable of improving stability of abrotani herba drug injection preparation | |
| CN106344503A (en) | Method for preparing pharmaceutical composition of lutein injection preparation | |
| CN106377592A (en) | Pharmaceutical composition for injection capable of improving stability of Yinzhihuang medication injection agent | |
| CN106344506A (en) | Preparation method of berberine injection preparation pharmaceutical composition | |
| CN107744501A (en) | A kind of medicinal composition for injections of tetrandrine | |
| CN106214629A (en) | A kind of preparation method of breviscapine drug injection preparation stability compositions | |
| CN106389314A (en) | Method for preparing injection preparation medicine compositions with fructus alpiniae oxyphyllae | |
| CN106138211A (en) | A kind of medicinal composition for injections improving Radix Illicii Lanceolati drug injection preparation stability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170208 |
|
| WW01 | Invention patent application withdrawn after publication |